



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## PX-12

Cat. No.:	HY-13734
CAS No.:	141400-58-0
Molecular Formula:	C <sub>7</sub> H <sub>12</sub> N <sub>2</sub> S <sub>2</sub>
Molecular Weight:	188.31
Target:	Others
Pathway:	Others
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

#### In Vitro

Ethanol : 50 mg/mL (265.52 mM; Need ultrasonic)  
 DMSO : ≥ 44.7 mg/mL (237.37 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		5.3104 mL	26.5520 mL	53.1039 mL
	5 mM		1.0621 mL	5.3104 mL	10.6208 mL
	10 mM		0.5310 mL	2.6552 mL	5.3104 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1 (Trx-1); inhibits the growth of MCF-7 and HT-29 cells with IC<sub>50</sub> values

	of 1.9 and 2.9 $\mu\text{M}$ , respectively.
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 1.9 (MCF-7), 2.9 $\mu\text{M}$ (HT-29 cells) <sup>[1]</sup>
<b>In Vitro</b>	<p>PX-12 inhibits the growth of MCF-7 and HT-29 cells with IC<sub>50</sub> values of 1.9 and 2.9 <math>\mu\text{M}</math>, respectively<sup>[1]</sup>. PX-12 particularly reduces the activity of Trx-1 by means of thio-alkylating critical cysteine residue (Cys73) which is located in the outside the conserved redox catalytic site of Trx-1. PX-12 affects the oxidation state of thiols in a number of cell surface proteins. Key surface receptors for platelet adhesion and activation are affected, including the collagen receptor GPVI and the von Willebrand factor receptor, GPIb. PX-12 inhibits thrombus formation over Type I collagen in whole blood under flow conditions<sup>[2]</sup>. Thioredoxin-1 (Trx-1) is a cellular redox protein that promotes tumor growth, inhibits apoptosis, and up-regulates hypoxia-inducible factor-1<math>\alpha</math> and vascular endothelial growth factor<sup>[3]</sup>. PX-12 inhibits the growth of colorectal cancer DLD-1 and SW620 cells in a dose- and time-dependent manner. PX-12 reduces cell colony formation and induced a G2/M phase arrest of the cell cycle. PX-12 treatment induces apoptosis. PX-12 inhibits colorectal cancer cell migration and invasion. Treatment of cancer cells with PX-12 reduces NOX1, CDH17 and S100A4 mRNA expression, and increases KLF17 mRNA expression. PX-12 decreases S100A4 protein expression in the colorectal cancer cells<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>PX-12 has been shown to have in vivo antitumor activity against human tumor xenografts including HT-29 colon cancer in SCID mice and has been tested in a phase I clinical trial in patients<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## CUSTOMER VALIDATION

- Free Radic Biol Med. 2022 Jul 31;189:157-168.
- Free Radic Biol Med. 2021 Dec 8;178:246-261.
- Front Immunol. 2021 Mar 9;12:625957.
- Ecotoxicol Environ Saf. 2022 Dec 1;247:114263.
- Ecotoxicol Environ Saf. 2022, 247: 114263.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Welsh SJ, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1 $\alpha$  and vascular endothelial growth factor formation. Mol Cancer Ther. 2003 Mar;2(3):235-43.
- [2]. Metcalfe C, et al. Thioredoxin Inhibitors Attenuate Platelet Function and Thrombus Formation. PLoS One. 2016 Oct 7;11(10):e0163006
- [3]. Ramanathan RK, et al. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14.
- [4]. Wang F, et al. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines. Oncol Rep. 2015 Feb;33(2):967-73.
- [5]. Lou M, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017 Jun 2;292(22):9136-9149.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA